Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository
TETRAD
1 other identifier
observational
200
1 country
9
Brief Summary
To stimulate collaborative efforts of federal funding agencies, voluntary health agencies, professional organizations and industry partners to enable creation of a large, sustainable database and repository to better understand the molecular basis of treatment and rapidly accelerate translational research in RA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2010
Typical duration for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2010
CompletedFirst Submitted
Initial submission to the registry
February 16, 2010
CompletedFirst Posted
Study publicly available on registry
February 17, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2012
CompletedOctober 14, 2015
October 1, 2015
2.5 years
February 16, 2010
October 12, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The number of enrolled patients will be used as a measure of success.
2 years
Study Arms (1)
RA patients/participants
Eligibility Criteria
Speciality/referral clinic, Community
You may qualify if:
- Age 19 years or older;
- Diagnosis of RA based on the cumulative presence of at least 4 of 7 ACR Criteria;
- Willing and able to provide informed consent; and
- One of the following:
- Starting MTX OR
- Previous or current use of Methotrexate and starting (or switching to) any of the following medications (with or without MTX)
- Etanercept
- Infliximab
- Adalimumab
- Rituximab
- Abatacept
- Golimumab
- Certolizumab
- Tocilizumab
- There is no minimum disease activity (number of swollen joints, DAS28, CRP or ESR, etc.) necessary for enrollment. Treatment decisions are entirely at the discretion of the treating rheumatologist.
- +2 more criteria
You may not qualify if:
- Concomitant diagnosis of RA and systemic lupus erythematosus, juvenile arthritis, psoriatic arthritis, hepatitis C infection, current pregnancy or lactation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Alabama at Birminghamlead
- Brigham and Women's Hospitalcollaborator
- Duke Universitycollaborator
- Johns Hopkins Universitycollaborator
- North Shore Medical Centercollaborator
- Stanford Universitycollaborator
- University of California, San Franciscocollaborator
- University of Colorado, Denvercollaborator
- University of Nebraskacollaborator
- University of Pittsburghcollaborator
Study Sites (9)
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Stanford University
Palo Alto, California, 94304, United States
University of Colorado in Denver
Aurora, Colorado, 80045, United States
Johns Hopkins University
Baltimore, Maryland, 21224, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68105, United States
North Shore Medical Center (LIJ Health System)
Lake Success, New York, 11042, United States
Duke University
Durham, North Carolina, 27710, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15261, United States
Related Publications (1)
Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C; TETRAD Investigators. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2099-105. doi: 10.1002/art.39675.
PMID: 26991245DERIVED
Biospecimen
Whole blood, red blood cells, white blood cells, plasma, serum, DNA, RNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
S. Louis Bridges, Jr., MD, PhD
University of Alabama at Birmingham
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Division of Clinical Immunology and Rheumatology
Study Record Dates
First Submitted
February 16, 2010
First Posted
February 17, 2010
Study Start
February 1, 2010
Primary Completion
August 1, 2012
Study Completion
August 1, 2012
Last Updated
October 14, 2015
Record last verified: 2015-10